2017 Chemotherapy Compounding 
Pharmacy Times
JUNE 27, 2025
Acalabrutinib had previously received approval in 2017 as a single agent for this same indication. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. The recent application was granted both priority review and orphan drug designation.
Pharmacy Times
JUNE 27, 2025
In the 2017 book The Big Picture , author Sean Carroll seamlessly blends the scientific with the philosophical and comments that “life is not a substance, like water or rock; it’s a process, like fire or a wave crashing on the shore. Dutton; 2017. REFERENCES 1. The Big Picture: On the Origins of Life, Meaning, and the Universe Itself.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Thyroid Pharmacist
AUGUST 1, 2025
Funny enough, in July 2017, on my 35th birthday, I told my husband I was ready to start a family, and went to a naturopathic clinic a few weeks later to get my labs done to prepare for pregnancy, when I realized my period was late! A practitioner will help assess individual patients to determine if or when breastfeeding is advised. [11]
pharmaphorum
JULY 18, 2025
Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
European Pharmaceutical Review
OCTOBER 19, 2023
With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?
European Pharmaceutical Review
JANUARY 3, 2023
Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers, yet they can cause ototoxicity, permanent and irreversible hearing loss, which occurs in up to 50-60 percent of adult patients and 90 percent of paediatric patients who survive cancer. This control arm will provide natural history data.
Pharmaceutical Technology
AUGUST 12, 2022
They were first licensed for use in 2017 for two forms of blood cancer, acute lymphoblastic leukemia (ALL), and B-cell lymphoma (BCL). By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. Overall, the global CAR-T cell market for all indications was worth $1.7
Expert insights. Personalized for you.
Let's personalize your content